MetaCap

Relmada Therapeutics Inc. (RLMD)

NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.62-0.49 (-15.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RLMD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$279.54M
EPS (TTM)
-$0.73
52-week range
2.60 – 8.00
Day range
2.60 – 3.13
Volume / Avg
2.25M / 1.45M
Beta
—

52-week range

$2.60$8.00

RLMD stock today

Relmada Therapeutics (RLMD) closed at $2.62 on Nov 20, down 15.76% (-$0.49), versus the S&P 500's 3.70% decline. Shares are 67.3% below their 52-week high of $8.00, set on May 6, 2026 and 0.7% above the 52-week low of $2.60, near the bottom of the past year's range. RLMD is down 45.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.6%.

Relmada Therapeutics has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Relmada Therapeutics

Company profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Headquarters
Coral Gables, FL
Employees
17

Financial highlights

Full financials

Relmada Therapeutics reported a net loss of $57.4 million, compared with a loss of $80.0 million a year earlier. Diluted earnings per share came in at -$1.45.

Relmada Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-57.39M$-79.98M$-98.79M$-157.04M$-125.75M
EPS (diluted)$-1.45$-2.65$-3.28$-5.30$-7.16

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$10.75+310.31%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.12 vs $-0.14
Surprise
+14.29%

RLMD news

All RLMD news

Relmada Therapeutics peers

Health Care sector
RLMD peer companies
CompanyPrice% ChgMarket capCompare
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs RLMD
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs RLMD
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs RLMD
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs RLMD
EVMNEvommune Inc.7.04-2.76%$291.10Mvs RLMD
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs RLMD
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs RLMD
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs RLMD

Indexes, lists and sector

Relmada Therapeutics stock FAQ

What is Relmada Therapeutics's stock price today?

RLMD last traded at $2.62 as of Nov 20, 4:00 PM EST, down 15.76% on the day. Prices are delayed at least 15 minutes.

Does Relmada Therapeutics pay a dividend?

No. Relmada Therapeutics does not currently pay a regular cash dividend.

Who is Relmada Therapeutics's CEO?

Dr. Sergio Traversa M.B.A., Pharm.D. is the chief executive officer of Relmada Therapeutics Inc., which has about 17 employees.

Has RLMD ever split its stock?

Yes. The most recent RLMD stock split was a 1-for-4 split on Sep 30, 2019, one of 2 splits on record.

What is the RLMD 52-week high?

The 52-week high for RLMD is $8.00 and the 52-week low is $2.60. The stock is currently 67.3% below its high.

Compare RLMD